KR102553815B1 - Cosmetic composition for preventing skin aging using poly-l-lactic acid - Google Patents
Cosmetic composition for preventing skin aging using poly-l-lactic acid Download PDFInfo
- Publication number
- KR102553815B1 KR102553815B1 KR1020220165076A KR20220165076A KR102553815B1 KR 102553815 B1 KR102553815 B1 KR 102553815B1 KR 1020220165076 A KR1020220165076 A KR 1020220165076A KR 20220165076 A KR20220165076 A KR 20220165076A KR 102553815 B1 KR102553815 B1 KR 102553815B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- plla
- cosmetic composition
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 239000002537 cosmetic Substances 0.000 title claims abstract description 47
- 230000009759 skin aging Effects 0.000 title abstract description 19
- 229920001432 poly(L-lactide) Polymers 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 33
- 102000008186 Collagen Human genes 0.000 claims abstract description 29
- 108010035532 Collagen Proteins 0.000 claims abstract description 29
- 229920001436 collagen Polymers 0.000 claims abstract description 29
- 230000037303 wrinkles Effects 0.000 claims abstract description 29
- 102000016942 Elastin Human genes 0.000 claims abstract description 28
- 108010014258 Elastin Proteins 0.000 claims abstract description 28
- 229920002549 elastin Polymers 0.000 claims abstract description 28
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 21
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 21
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 229920000575 polymersome Polymers 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 235000004347 Perilla Nutrition 0.000 claims description 15
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229940107161 cholesterol Drugs 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 2
- AEMOLEFTQBMNLQ-PKKLWIBTSA-N D-Alluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-PKKLWIBTSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000035515 penetration Effects 0.000 abstract description 9
- 206010059516 Skin toxicity Diseases 0.000 abstract description 7
- 231100000438 skin toxicity Toxicity 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 48
- 238000002360 preparation method Methods 0.000 description 13
- 239000002502 liposome Substances 0.000 description 12
- 230000032683 aging Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물에 관한 것으로, 더욱 상세하게는 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부노화 방지 효과를 나타낼 뿐만 아니라, 피부독성이 낮아 피부트러블을 유발하지 않는 효과를 나타내는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA), and more specifically, it is applicable to the MTS method and exhibits an excellent skin aging prevention effect due to the improvement of skin penetration effect, It relates to a cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA), which has low toxicity and does not cause skin trouble.
댄 벨스키 미국 듀크대 교수 연구팀은 954명을 대상으로 12년간 추적조사를 진행한 끝에 노화는 26세부터 시작되며 신체나이가 38세에 이르렀을 때 노화가 가장 빠르게 진행된다는 사실을 발견했다. 연구팀은 1972~1973년에 태어난 뉴질랜드에 사는 성인들을 대상으로 연구를 진행했다. 신체 내부를 측정하기 위해 신장, 간, 폐, 대사 및 면역기능, 콜레스테롤 수치, 심폐기능, 치아 상태 등을 지표로 사용했다. 또한 염색체의 끝 부분에서 세포분열을 조절해 노화를 결정하는 텔로미어의 길이와, 눈 뒤쪽 모세혈관의 상태를 포함해 총 18가지 항목으로 신체나이를 측정했다. 노화가 시작되면서 피부 또한 25세 기준으로 피부 재생 세포가 감소하게 된다. 노화 뿐만 아니라 외부의 각종 유해환경 및 스트레스에 노출되어 여러 손상을 받고 있는 현대인들의 피부는 나이가 들어감에 따라 생리 활성이 저하되면서 주름, 탄력저하, 건조 등 여러 피부 노화 현상도 경험하게 된다. 평균수명이 늘어남에 따라 이런 노화증세를 개선하기 위한 화장료의 개발에 필요성을 더욱 두게 된다. 생화학 및 분자생물학의 발전을 기반으로 하여 우리 생체 내에 존재하는 성장인자와 같은 소량의 신호물질들이 발견되었으며, 이를 기반으로 한 생체의 노화 이론이 재정립되고 있다. 또한 이 신호물질은 나이가 증가함에 따라 생체 내에서 감소하게 되는데 이는 콜라겐, 엘라스틴, 히알루론산의 감소가 우리 노화와 밀접한 관련이 있다는 것을 밝히고 있다. 나이가 들어감에 따라 이 세 가지 성분이 감소하게 되면서 피부탄력 감소, 피부주름, 색소침착 등 피부노화현상이 나타나게 된다. 피부표피와 진피에서 나타나는 현상인 콜라겐의 파괴, 콜라겐 합성의 감소, 엘라스틴의 소실 및 피부생리 저하에 따른 멜라닌 색소침착 등에 의한 현상 등을 개선하기 위하여 다양한 화장료가 개발되어 지고 있다. After conducting a 12-year follow-up on 954 people, a research team led by Professor Dan Belsky of Duke University found that aging begins at the age of 26 and accelerates when the body reaches 38 years of age. The research team studied adults living in New Zealand who were born between 1972 and 1973. To measure the inside of the body, kidney, liver, lung, metabolism and immune functions, cholesterol levels, cardiopulmonary function, and dental conditions were used as indicators. In addition, telomere length, which determines aging by regulating cell division at the end of chromosomes, and the state of capillaries in the back of the eyes, were measured by a total of 18 items, including body age. As aging begins, skin regenerative cells also decrease by the age of 25. In addition to aging, modern people's skin, which is exposed to various external harmful environments and stresses, is exposed to various damages. As the average lifespan increases, there is a need to develop cosmetics to improve these signs of aging. Based on the development of biochemistry and molecular biology, a small amount of signal substances such as growth factors that exist in our body have been discovered, and based on this, the aging theory of the living body is being reestablished. In addition, this signal substance decreases in vivo as age increases, which reveals that the decrease in collagen, elastin, and hyaluronic acid is closely related to our aging. As these three components decrease with age, skin aging phenomena such as reduced skin elasticity, skin wrinkles, and pigmentation appear. Various cosmetics are being developed to improve phenomena such as destruction of collagen, decrease in collagen synthesis, loss of elastin, and melanin pigmentation due to deterioration of skin physiology, which are phenomena appearing in the skin epidermis and dermis.
인체를 구성하고 있는 기관 중 가장 큰 기관인 피부는 면적 1.8m2, 두께 2~4mm, 무게 3kg으로 여러 개의 상이한 층들로 구성되고, 각 층은 특화된 기능을 갖으며 주요한 층들은 표피층(epidermis), 진피층(dermis) 등으로 구성되어 있다. 표피층은 가장 피부 겉면으로 각질층, 투명층, 과립층, 유극층, 기저층 총 5가지로 나뉘고 있다. 표피층에 있는 투명층과 과립층 사이에는 수분저지막이 있는데, 이는 화학적 성질을 지난 특수막으로 외부로부터 이물질의 침투를 막고 피부내부로부터의 수분이 날아가는 것을 막아주는 역할을 하고 있다. 이 수분저지막으로 인해 이물질 뿐만 아니라 물도 내부로 침입할 수 없는데, 이로인해 화장품의 유효성분 또한 피부 깊숙이 침투가 어려워 지게 된다. 진피층은 피부조직의 90% 이상을 차지하고 있어서 피부모양을 결정짓는 진짜 피부라고도 하여 진피라고 불리는데 진피층은 유두층과 망상층으로 나뉘고 있다. 유두층 아래한 망상층은 단단하고 불규칙적인 그물모양을 결합조직으로 진피층의 대부분을 차지하고 있는데, 콜라겐, 엘라스틴, 히알루론산등으로 구성되어 있다.The skin, which is the largest organ of the human body, is composed of several different layers with an area of 1.8 m2, a thickness of 2 to 4 mm, and a weight of 3 kg. Each layer has a specialized function, and the main layers are the epidermis and dermis ( dermis), etc. The epidermal layer is the outermost layer of the skin and is divided into five layers: the stratum corneum, the clear layer, the granular layer, the spinous layer, and the basal layer. There is a moisture barrier layer between the transparent layer and the granular layer in the epidermal layer, which is a special membrane that has passed chemical properties and serves to prevent the penetration of foreign substances from the outside and the escape of moisture from the inside of the skin. Due to this moisture-blocking film, not only foreign substances but also water cannot penetrate into the skin, which makes it difficult for the active ingredients of cosmetics to penetrate deep into the skin. The dermis layer occupies more than 90% of the skin tissue, so it is called the dermis because it is called the real skin that determines the skin shape. The reticular layer under the papillary layer is a hard and irregular net-shaped connective tissue that occupies most of the dermal layer, and is composed of collagen, elastin, and hyaluronic acid.
한편, 물리적 경피 흡수방법인 MTS(Microneedle Therapy System)는 인체의 안정성과 효용성이 확립되어 있는 미세침으로, 화장품 제형의 흡수를 촉진하는데 효과적인 방법으로 사료되는 것이 입증되어 있다. 0.25mm~0.5mm의 아주 미게한 계획적인 통로를 물리적으로 만들어 유효성분의 흡수율을 80%이상 끌어올리기 위한 기기이다. 아무리 저분자의 화장품이라고 해도 단순 도포시에는 흡수율은 10%가 넘기기 어려운 일이기에 물리적으로 미세틈을 만들어 흡수율을 높이도록 한다. 가정용 니들로 안정성을 입증했다고 하여도 미세침으로 인한 상처가 발생할 수 있다. On the other hand, MTS (Microneedle Therapy System), a physical percutaneous absorption method, is a fine needle for which the safety and effectiveness of the human body has been established, and it has been proven to be considered an effective method for promoting absorption of cosmetic formulations. It is a device to increase the absorption rate of active ingredients by more than 80% by physically creating a very fine planned passage of 0.25mm to 0.5mm. No matter how low-molecular cosmetics are, when simply applied, the absorption rate is difficult to exceed 10%, so physically create fine gaps to increase the absorption rate. Even if safety has been proven with household needles, fine needles can cause wounds.
생화학 및 분자생물학의 발전을 기반으로 하여 우리 생체 내에 존재하는 성장인자와 같은 소량의 신호물질들이 발견되었으며, 이를 기반으로 한 생체의 노화 이론이 재정립되고 있다. 또한 이 신호물질은 나이가 증가함에 따라 생체 내에서 감소하게 되는데 바로 콜라겐, 히알루론산, 엘라스틴의 감소가 우리의 노화와 밀접한 관계가 있다는 것이 밝혀지고 있다. 콜라겐은 아미노산이 모여 구성된 단백질의 일종으로 세포나 조직을 접착제처럼 결합시켜 세포 활동의 발판 역할을 하며, 체내 세포와 세포 사이에 존재하여 모든 세포를 연결하는 역할을 한다. 엘라스틴은 스프링 모양의 경단백질이며 , 콜라겐 사이에 존재하며 결혼 조직으로 얽혀 있다. 스프링 구조로 되어있기 때문에, 엘라스틴 함량이 줄면 구조가 느슨해져 피부가 쉽게 쳐지고 잔주름이 생길 가능성이 높다. 히알루론산은 눈의 소자체, 닭의 벼슬, 관절액 등 동물의 결합조직에 널리 존재하고 있는 산성 뮤코다당류의 일종으로 N-아세틸-D-글루코사민과 D-글루큐론산을 반복구성단위로 하는 고분자 물질이다. 타 뮤코다당류에 비해 분자량이 크고 매우 높은 수분 흡수력을 가지고 있다. 1g의 히알루론산은 수중에서 약 1L의 체적을 차지한다는 보고가 있다. 피부는 노화가 진행되기 전에는 피부세포의 생리활성이 활발하다. 진피에 있는 섬유아세포에서는 콜라겐의 합성과 신진대사가 왕성하며 히알루론산, 엘라스틴을 포함한 당단백질류인 GAGS합성도 활발하여 피부에 탄력성, 부드러움, 유연성 및 보습성을 부여한다. 그러나 현대인의 피부는 외부의 각종 유해 환경 및 스트레스에 노출되어 다양한 손상을 받고 있고, 나이가 들면서 피부의 생리활성이 저하되고 손상된 피부의 회복속도가 느려지면서 피부는 탄력 저하, 건조, 주름 형성, 색소침착, 검버섯, 칙칙함 등의 다양한 피부 노화 현상이 나타난다. 이러한 피부의 문제를 해결하기 위해 해당 원료들을 포함하는 화장료 조성물이 필요할 수 있다. Based on the development of biochemistry and molecular biology, a small amount of signal substances such as growth factors that exist in our body have been discovered, and based on this, the aging theory of the living body is being reestablished. In addition, this signal substance decreases in vivo as age increases, and it is revealed that the decrease in collagen, hyaluronic acid, and elastin is closely related to our aging. Collagen is a type of protein made up of amino acids. It serves as a scaffold for cell activities by binding cells or tissues like glue, and plays a role in connecting all cells by existing between cells in the body. Elastin is a spring-shaped hard protein, present between collagen and entangled in marriage tissue. Since it has a spring structure, when the elastin content is reduced, the structure becomes loose, which makes the skin more likely to sag and cause fine wrinkles. Hyaluronic acid is a type of acidic mucopolysaccharide widely present in connective tissues of animals such as eye elements, chicken crests, and joint fluid. am. Compared to other mucopolysaccharides, it has a high molecular weight and very high water absorption. There is a report that 1 g of hyaluronic acid occupies a volume of about 1 L in water. Before skin aging progresses, the physiological activity of skin cells is active. In fibroblasts in the dermis, the synthesis and metabolism of collagen are vigorous, and the synthesis of GAGS, a type of glycoprotein including hyaluronic acid and elastin, is also active, giving elasticity, softness, flexibility and moisture to the skin. However, modern people's skin is exposed to various external harmful environments and stresses, resulting in various damages. Various skin aging phenomena such as calmness, age spots, and dullness appear. In order to solve these skin problems, a cosmetic composition containing the corresponding raw materials may be required.
또한, 리포좀은 현재 제약 분야 뿐 만 아니라 화장품, 식품 등에도 널리 이용되는 있는데 이는 생리활성 성분을 안정하게 전달할 수 있다는 장점을 갖고 있다. 정맥주사, 척수주사와 같은 주사로 쓰이기도 하고 상처가 났을 때 바르는 연고로 사용되기도 한다. 이는 연고안에 유효한 성분들이 피부 겉표면인 표피가 아닌 진피 안에 침투되도록 하여 피부 재생을 촉진시키기 위함인데, 이같은 성질은 화장품분야에서도 사용이 되어 지고 있다. 화장품에서 리포좀의 유용성은 소수성(Hydrophobic)인 피부에 대해 흡수 및 친화성이 작은 수용성(Water-soluble) 유효성분을 인지질로 된 리포좀 내에 포접하는 것으로 표피층의 수분저지막을 통과 하면서 피부흡수의 문제를 개선할 수 있는 특성을 가지고 있다. 리포좀은 크게 다막리포좀(MLV:Multilamella vesicle)과 단막리포좀(ULV:Unilamella vesicle)로 구분되고 ULV는 다사 대단막리포좀(Large Unilamella vesicle)과 소단막리포좀(Small Unilamella vesicle)으로 나눌 수 있다. MLV는 그 크기가 500~5,500nm(나노미터)이고 리포좀 안에 내포시킬 수 있는 량은 5~15%이고, LUV는 그 크기가 200~800nm 이고 리포 좀 안에 내포시킬 수 있는 량은 36~65%이고, SUV는 크기는 20~ 150nm이며, 리포좀 안에 내포시킬 수 있는 량은 0.5~1.0%이다. 생리활성 물 질을 내포시 킬 수 있는 양은 LUV가 가장 많으나 불안정하고, 사람의 피부 의 구조는 다막(Multilamella)의 구조를 갖고 있어 MLV는 피부와 친화력이 있으나 크기가 너무 커 피부 침투가 어렵다. 그래서 화장품에서 사용되는 리포좀 입자는 피부내 전달에 있어서 안정성과 유효성을 가져야 하기 때 문에 SUV형태일 때 더 높은 것으로 사료된다. 더불어 콜라겐, 엘라스틴, 히 알루 론산과 같이 피부층보다 큰 고분자물질을 리포좀 공법을 통하여 분 자량을 쪼개어 침투율을 높일 수 있다. 입자크기를 최소한 친수성 물질로, 피부와 유사한인지질로 되어 피부 깊숙이 유효성분들을 전달 하도록 한다.In addition, liposomes are currently widely used not only in pharmaceutical fields but also in cosmetics and foods, which have the advantage of being able to stably deliver physiologically active ingredients. It is used for injections such as intravenous and spinal injections, and is also used as an ointment for wounds. This is to promote skin regeneration by allowing effective ingredients in the ointment to penetrate into the dermis rather than the epidermis, which is the outer surface of the skin, and this property is also being used in the cosmetic field. The usefulness of liposomes in cosmetics is to encapsulate water-soluble active ingredients with low absorption and affinity for the hydrophobic skin in liposomes made of phospholipids, thereby improving skin absorption problems while passing through the water barrier of the epidermal layer. It has the ability to do it. Liposomes are largely classified into multilamellar vesicles (MLV) and Unilamella vesicles (ULV), and ULVs can be divided into large unilamella vesicles and small unilamella vesicles. MLV has a size of 500-5,500 nm (nanometers) and the amount that can be encapsulated in liposomes is 5-15%, and LUV is 200-800 nm in size and the amount that can be encapsulated in liposomes is 36-65% , and the size of the SUV is 20 to 150 nm, and the amount that can be encapsulated in the liposome is 0.5 to 1.0%. LUV has the highest amount of bioactive substances, but it is unstable, and the structure of human skin has a multilamella structure, so MLV has affinity with the skin, but it is too large to penetrate the skin. Therefore, it is considered that the liposome particles used in cosmetics are higher in SUV form because they must have stability and effectiveness in intradermal delivery. In addition, the penetration rate can be increased by splitting the molecular weight of polymers larger than the skin layer, such as collagen, elastin, and hyaluronic acid, through the liposome method. The particle size is at least a hydrophilic material and a phospholipid similar to that of the skin to deliver active ingredients deep into the skin.
본 발명의 목적은 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부노화 방지 효과를 나타낼 뿐만 아니라, 피부독성이 낮아 피부트러블을 유발하지 않는 효과를 나타내는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물을 제공하는 것이다.An object of the present invention is to use polyelastic acid (PLLA), which is applicable to the MTS method and exhibits an excellent skin aging prevention effect due to improved skin penetration, as well as an effect that does not cause skin trouble due to low skin toxicity. It is to provide a cosmetic composition for improving skin wrinkles.
본 발명의 목적은 유효성분 100 중량부 및 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀 0.1 내지 10 중량부로 이루어지며, 상기 유효성분은 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 함유되는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용하여 피부노화 방지용 화장료 조성물을 제공함에 의해 달성된다.The object of the present invention consists of 100 parts by weight of an active ingredient and 0.1 to 10 parts by weight of a polymersome containing polyelastic acid (PLLA), and the active ingredient contains sodium hyaluronate, collagen and hydrolyzed elastin. It is achieved by providing a cosmetic composition for preventing skin aging using polyelastic acid (PLLA), characterized in that it becomes.
본 발명의 바람직한 특징에 따르면, 상기 유효성분은 글리세린, 정제수, 카프릴릭/카프릭트라이글리세라이드, 하이드로제네이티드레시틴, 콜레스테롤, 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴으로 이루어지는 것으로 한다.According to a preferred feature of the present invention, the active ingredient is composed of glycerin, purified water, caprylic/capric triglyceride, hydrogenated lecithin, cholesterol, sodium hyaluronate, collagen, and hydrolyzed elastin. .
본 발명의 더 바람직한 특징에 따르면, 상기 유효성분은 글리세린 100 중량부, 정제수 13 내지 17 중량부, 카프릴릭/카프릭트라이글리세라이드 5 내지 7 중량부, 하이드로제네이티드레시틴 2 내지 3 중량부, 콜레스테롤 0.5 내지 0.7 중량부, 소듐하이알루로네이트 0.1 내지 0.15 중량부, 콜라겐 0.1 내지 0.15 중량부 및 하이드롤라이즈드엘라스틴 0.1 내지 0.15 중량부으로 이루어지는 것으로 한다.According to a more preferred feature of the present invention, the active ingredient is glycerin 100 parts by weight, purified water 13 to 17 parts by weight, caprylic / capric triglyceride 5 to 7 parts by weight, hydrogenated lecithin 2 to 3 parts by weight, 0.5 to 0.7 parts by weight of cholesterol, 0.1 to 0.15 parts by weight of sodium hyaluronate, 0.1 to 0.15 parts by weight of collagen, and 0.1 to 0.15 parts by weight of hydrolyzed elastin.
본 발명의 더욱 바람직한 특징에 따르면, 상기 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 120 내지 200 나노미터로 에멀전화되는 것으로 한다.According to a more preferred feature of the present invention, the sodium hyaluronate, collagen and hydrolyzed elastin are emulsified to 120 to 200 nanometers.
본 발명의 더욱 더 바람직한 특징에 따르면, 상기 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀은 폴리엘락틱엑시드(PLLA)와 폴리에틸렌글리콜이 5:2로 혼합된 혼합물에 팔미토일트리펩타이드를 첨가하여 제조되는 것으로 한다.According to a more preferred feature of the present invention, the polyelastic acid (PLLA)-containing polymersome is obtained by adding palmitoyl tripeptide to a mixture of polyelastic acid (PLLA) and polyethylene glycol in a ratio of 5: 2. to be manufactured.
본 발명의 더욱 더 바람직한 특징에 따르면, 상기 유효성분에는 상기 유효성분에 함유된 글리세린 100 중량부 대비 들깻잎 추출물 0.1 내지 5 중량부가 더 함유되는 것으로 한다.According to a more preferred feature of the present invention, the active ingredient further contains 0.1 to 5 parts by weight of perilla leaf extract relative to 100 parts by weight of glycerin contained in the active ingredient.
본 발명의 더욱 더 바람직한 특징에 따르면, 상기 들깻잎 추출물은 들깻잎 100 중량부에 탄소수가 1 내지 4인 저급알코올 200 내지 1000 중량부를 혼합하고 추출하여 제조되는 것으로 한다.According to a more preferred feature of the present invention, the perilla leaf extract is prepared by mixing and extracting 200 to 1000 parts by weight of lower alcohol having 1 to 4 carbon atoms in 100 parts by weight of perilla leaves.
본 발명의 더욱 더 바람직한 특징에 특징에 따르면, 상기 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물은 화장수, 아이크림, 수분크림, 클렌징제품, 세럼 및 앰플로 이루어진 그룹에서 선택된 하나의 제형으로 적용되는 것으로 한다.According to a more preferred feature of the present invention, the cosmetic composition for skin wrinkle improvement using the polyelastic acid (PLLA) is one selected from the group consisting of lotion, eye cream, moisture cream, cleansing product, serum and ampoule It is to be applied as a formulation.
본 발명에 따른 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물은 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부노화 방지 효과를 나타낼 뿐만 아니라, 피부독성이 낮아 피부트러블을 유발하지 않는 효과를 나타내는 화장료 조성물을 제공하는 탁월한 효과를 나타낸다.The cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA) according to the present invention can be applied to the MTS method and exhibits excellent skin aging prevention effects due to improved skin penetration effect, as well as low skin toxicity, so as to prevent skin troubles. It shows an excellent effect of providing a cosmetic composition exhibiting an effect that does not induce.
이하에는, 본 발명의 바람직한 실시예와 각 성분의 물성을 상세하게 설명하되, 이는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 발명을 용이하게 실시할 수 있을 정도로 상세하게 설명하기 위한 것이지, 이로 인해 본 발명의 기술적인 사상 및 범주가 한정되는 것을 의미하지는 않는다.Hereinafter, a preferred embodiment of the present invention and the physical properties of each component will be described in detail, but this is to be explained in detail so that a person having ordinary knowledge in the art to which the present invention belongs can easily practice the invention, This is not meant to limit the technical spirit and scope of the present invention.
본 발명에 따른 폴리엘락틱엑시드(PLLA)를 이용하여 피부노화 방지용 화장료 조성물은 유효성분에 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀을 혼합하여 이루어지며, 유효성분 100 중량부 및 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀 0.1 내지 10 중량부로 이루어지는 것이 바람지하다.The cosmetic composition for preventing skin aging using polyelastic acid (PLLA) according to the present invention is made by mixing a polymersome containing polyelastic acid (PLLA) with an active ingredient, 100 parts by weight of active ingredient and polyellactic acid It is preferable to consist of 0.1 to 10 parts by weight of polymersome containing acid (PLLA).
상기 유효성분은 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 함유되는데, 상기의 성분이 함유된 유효성분은 우수한 피부노화 방지 및 주름개선 효과를 나타낸다.The active ingredient contains sodium hyaluronate, collagen, and hydrolyzed elastin, and the active ingredient containing the above ingredients exhibits excellent anti-aging and anti-wrinkle effects.
또한, 상기 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 나이가 들수록 감소하는 진피층에서 감소하는 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴 성분을 보충해 피부노화나 주름방지효과를 부여하는 역할을 한다.In addition, the sodium hyaluronate, collagen, and hydrolyzed elastin supplement the sodium hyaluronate, collagen, and hydrolyzed elastin components that decrease in the dermal layer, which decreases with age, to prevent skin aging or wrinkles. role in giving
또한, 상기의 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 피부 깊이 침투할 수 있도록 리포좀공법을 통해 리포좀화하는 것이 바람직하며, 이때, 상기와 같이 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀을 혼합하여 리포좀화하는 것이 바람직하다.In addition, it is preferable to liposome through a liposome method so that the sodium hyaluronate, collagen, and hydrolyzed elastin can penetrate deeply into the skin. At this time, as described above, polyelastic acid (PLLA) containing Preferably, liposomes are mixed with polymersomes.
또한, 상기의 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 75 내지 80℃의 온도로 가열된 상태에서 고압균질기로 교반한 후에 40℃로 냉각하고, 마이크로에멀전화기기(Microfluidizer, MFD)를 이용하여 평균입자가 120 내지 200 나노미터를 나타내도록 한 후에 에멀전화되는 것이 바람직하다.In addition, the above sodium hyaluronate, collagen and hydrolyzed elastin were stirred with a high-pressure homogenizer in a state heated to a temperature of 75 to 80 ° C, cooled to 40 ° C, and microemulsified device (Microfluidizer, MFD) It is preferable to emulsify after making the average particle exhibit 120 to 200 nanometers by using.
상기와 같이 마이크로에멀전화기기를 이용하여 7 내지 10회 처리하게 되면 평균입자가 약 120 내지 150 나노미터를 나타내게 되며, 마이크로에멀전화기기를 이용하여 10 내지 20회 처리하게 되면 150 내지 200 나노미터의 평균입자 크기를 나타내게 된다.As described above, when treated 7 to 10 times using a microemulsion machine, the average particle shows about 120 to 150 nanometers, and when treated 10 to 20 times using a microemulsion machine, 150 to 200 nanometers Indicates the average particle size.
상기와 같은 평균입자크기를 나타내는 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 피부침투 효과가 월등하게 향상된다.Sodium hyaluronate, collagen, and hydrolyzed elastin exhibiting the average particle size as described above significantly improve the skin penetration effect.
이때, 상기 유효성분은 글리세린, 정제수, 카프릴릭/카프릭트라이글리세라이드, 하이드로제네이티드레시틴, 콜레스테롤, 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴으로 이루어지는 것이 바람직하며, 글리세린 100 중량부, 정제수 13 내지 17 중량부, 카프릴릭/카프릭트라이글리세라이드 5 내지 7 중량부, 하이드로제네이티드레시틴 2 내지 3 중량부, 콜레스테롤 0.5 내지 0.7 중량부, 소듐하이알루로네이트 0.1 내지 0.15 중량부, 콜라겐 0.1 내지 0.15 중량부 및 하이드롤라이즈드엘라스틴 0.1 내지 0.15 중량부으로 이루어지는 것이 더욱 바람직하다.At this time, the active ingredient is preferably composed of glycerin, purified water, caprylic / capric triglyceride, hydrogenated lecithin, cholesterol, sodium hyaluronate, collagen and hydrolyzed elastin, 100 parts by weight of glycerin , 13 to 17 parts by weight of purified water, 5 to 7 parts by weight of caprylic/capric triglyceride, 2 to 3 parts by weight of hydrogenated lecithin, 0.5 to 0.7 parts by weight of cholesterol, 0.1 to 0.15 parts by weight of sodium hyaluronate , It is more preferably composed of 0.1 to 0.15 parts by weight of collagen and 0.1 to 0.15 parts by weight of hydrolyzed elastin.
상기 글리세린 100 중량부 대비 소듐하이알루로네이트의 함량이 0.1 중량부 미만이면 노화방지효과가 저하되며, 상기 소듐하이알루로네이트의 함량이 0.15 중량부를 초과하게 되면 본 발명을 통해 제조되는 피부노화 방지용 화장료 조성물의 점도가 지나치게 증가하여 MTS공법에 적용이 어려워진다.When the content of sodium hyaluronate is less than 0.1 part by weight relative to 100 parts by weight of the glycerin, the anti-aging effect is reduced, and when the content of sodium hyaluronate exceeds 0.15 part by weight, for preventing skin aging produced through the present invention The viscosity of the cosmetic composition increases excessively, making it difficult to apply to the MTS method.
또한, 상기 유효성분에는 상기 유효성분에 함유된 글리세린 100 중량부 대비 들깻잎 추출물 0.1 내지 5 중량부가 더 함유되는데, 피부 탄력도 개선 및 피부 주름 개선 효과를 부여하는 역할을 한다.In addition, the active ingredient further contains 0.1 to 5 parts by weight of perilla leaf extract compared to 100 parts by weight of glycerin contained in the active ingredient, which serves to improve skin elasticity and improve skin wrinkles.
상기 들깻잎 추출물은 들깻잎 100 중량부에 탄소수가 1 내지 4인 저급알코올 200 내지 1000 중량부를 혼합하고 추출하여 제조되는데, 상기의 과정을 통해 제조되는 들깻잎 추출물에는 MMP 유전자 발현 억제 효과를 나타내는 루테올린-디글루쿠로나이드, 아피게닌-디글루쿠로나이드, 루테올린-글루쿠로나이드 및 로즈마리네이트로 이루어진 군으로부터 선택되는 하나 이상의 화합물이 함유되어 우수한 피부 탄력도 개선 및 피부 주름 개선 효과를 나타낸다.The perilla leaf extract is prepared by mixing and extracting 200 to 1000 parts by weight of lower alcohol having 1 to 4 carbon atoms with 100 parts by weight of perilla leaf. It contains at least one compound selected from the group consisting of glucuronide, apigenin-diglucuronide, luteolin-glucuronide, and rosmarinate, and exhibits excellent skin elasticity improvement and skin wrinkle improvement effects.
상기 들깻잎 추출물의 함량이 0.1 중량부 미만이면 상기의 효과가 미미하며, 상기 들깻잎 추출물의 함량이 5 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 화장료 조성물의 제형안정성이 저하될 수 있기 때문에 바람직하지 못하다.If the content of the perilla leaf extract is less than 0.1 parts by weight, the above effect is insignificant, and if the content of the perilla leaf extract exceeds 5 parts by weight, the above effect is not greatly improved, and the formulation stability of the cosmetic composition may be reduced. not desirable
상기 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀은 0.1 내지 10 중량부가 함유되며, 폴리엘락틱엑시드(PLLA)와 폴리에틸렌글리콜이 5:2로 혼합된 혼합물에 팔미토일트리펩타이드를 첨가하여 제조되는데, 지질과 유사한 생체적합, 생분해성 고분자의 자기회합에 의한 분자 이중층 베지클로 펩타이드와 폴리머좀의 박막과 흡착하지 않아 내부의 펩타이드와 같은 효능 물질 뿐만 아니라, 상기 유효성분의 변성을 근본적으로 차단하여 고유 활성을 온전히 유지시켜 줄 수 있는 장점을 나타낸다.The polyelastic acid (PLLA)-containing polymersome contains 0.1 to 10 parts by weight, and is prepared by adding palmitoyl tripeptide to a mixture of polyelastic acid (PLLA) and polyethylene glycol at a ratio of 5: 2. , Lipid-like biocompatibility and self-association of biodegradable polymers do not adsorb to the molecular double-layered vesiclo peptide and the thin film of the polymersome, thereby fundamentally blocking the denaturation of the active ingredient as well as effective substances such as internal peptides. It shows the advantage that can keep the activity intact.
상기 폴리머좀은 입자 직경이 300 내지 1000 나노미터를 나타내며, 피부 흡수가 가능한 크기로 합성되는데, 상기 팔미토일트리펩타이드는 폴리머좀 총 중량에 대하여 0.0001∼1 중량%로 함유되는 것이 바람직한데, 상기의 성분으로 이루어지는 폴리머좀은 상기 유효성분의 피부침투 효과를 향상시킬 뿐만 아니라, 폴리머좀 자체에 팔미토일트리펩타이드 성분이 함유되어 피부노화 방지효과를 더욱 향상시킬 수 있다.The polymersome has a particle diameter of 300 to 1000 nanometers and is synthesized in a size that can be absorbed into the skin. The polymersome composed of ingredients not only enhances the skin penetration effect of the active ingredient, but also contains the palmitoyl tripeptide component in the polymersome itself, so that the skin aging prevention effect can be further improved.
상기 폴리머좀의 함량이 0.1 중량부 미만이면 상기의 효과가 미미하며, 상기 폴리머좀의 함량이 10 중량부를 초과하게 되면 상대적으로 유효성분의 함량이 지나치게 줄어들어 피부노화 방지 효과가 저하될 뿐만 아니라, 화장료 조성물의 점도가 지니치게 증거하여 MTS공법에 적용이 어려울 수 있다.If the content of the polymersome is less than 0.1 part by weight, the above effect is insignificant, and if the content of the polymersome exceeds 10 parts by weight, the content of the active ingredient is relatively excessively reduced, thereby reducing the effect of preventing skin aging, as well as cosmetic The viscosity of the composition is too strong, so it may be difficult to apply it to the MTS method.
상기의 성분으로 이루어지는 피부노화 방지용 화장료 조성물은 그 제형이 특별히 한정되지 않지만, 피부노화 방지효과를 위해 사용빈도수나 피부에 적용되는 부분을 고려했을 때, 화장수, 아이크림, 수분크림, 클렌징제품, 세럼 및 앰플로 이루어진 그룹에서 선택된 하나의 제형으로 적용되는 것이 바람직하다.The formulation of the anti-aging cosmetic composition comprising the above components is not particularly limited, but considering the frequency of use or the part applied to the skin for the anti-skin aging effect, lotion, eye cream, moisturizing cream, cleansing product, serum And it is preferably applied in one formulation selected from the group consisting of ampoules.
이하에서는, 본 발명에 따른 폴리엘락틱엑시드(PLLA)를 이용하여 피부노화 방지용 화장료 조성물의 제조방법 및 그 제조방법으로 제조된 화장료 조성물의 물성을 실시예를 들어 설명하기로 한다.Hereinafter, a method for preparing a cosmetic composition for preventing skin aging using polyelastic acid (PLLA) according to the present invention and physical properties of the cosmetic composition prepared by the manufacturing method will be described with examples.
<제조예 1><Production Example 1>
소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴 각각을 78℃의 온도로 가열한 상태에서 고압균질기로 교반한 후에 40℃로 냉각하고, 마이크로에멀전화기기(Microfluidizer, MFD)를 이용하여 평균입자가 120 내지 200 나노미터를 나타내도록 하였다.Sodium hyaluronate, collagen, and hydrolyzed elastin were each heated to a temperature of 78 ° C, stirred with a high-pressure homogenizer, cooled to 40 ° C, and averaged by using a microfluidizer (MFD) was made to represent 120 to 200 nanometers.
<제조예 2> 유효성분의 제조<Preparation Example 2> Preparation of active ingredient
글리세린 80.2g, 정제수 12mL, 카프릴릭/카프릭트라이글리세라이드 5g, 하이드로제네이티드레시틴 2g, 콜레스테롤 0.5g, 상기 제조예 1을 통해 제조된 소듐하이알루로네이트 0.1g, 콜라겐 0.1g 및 하이드롤라이즈드엘라스틴 0.1g을 혼합하여 유효성분을 제조하였다.80.2g of glycerin, 12mL of purified water, 5g of caprylic/capric triglyceride, 2g of hydrogenated lecithin, 0.5g of cholesterol, 0.1g of sodium hyaluronate prepared in Preparation Example 1, 0.1g of collagen and hydrol An active ingredient was prepared by mixing 0.1 g of lyzed elastin.
<제조예 3> 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀의 제조<Preparation Example 3> Preparation of polymersomes containing polyelastic acid (PLLA)
클로로포름에 폴리엘락틱엑시드(PLLA)와 폴리에틸렌글리콜을 5:2 중량비로 혼합하여 용해한 후 반응물의 전체 중량에 대하여 1중량%의 팔미토일트리펩타이드-5를 첨가한 후에, 마이크로플루딕스 기술을 통해 폴리머좀을 합성한 후 클로로포름을 제거하고 경화시켜 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀을 제조하였다.After mixing and dissolving polyelastic acid (PLLA) and polyethylene glycol in a 5:2 weight ratio in chloroform, 1% by weight of palmitoyl tripeptide-5 based on the total weight of the reactants was added, and then the polymer was dissolved through microfluidics technology. After synthesizing the bit, chloroform was removed and cured to prepare a polymer bit containing polyelastic acid (PLLA).
<제조예 4> 들깻잎 추출물의 제조<Preparation Example 4> Preparation of perilla leaf extract
들깻잎 100 중량부에 질량농도가 50%인 에탄올 800 중량부를 혼합하고 전자레인지에 투입하고 90W에서 5분 동안 가열하여 들깻잎 추출물을 제조하였다.800 parts by weight of ethanol having a mass concentration of 50% was mixed with 100 parts by weight of perilla leaves, put in a microwave oven, and heated at 90W for 5 minutes to prepare a perilla leaf extract.
<실시예 1><Example 1>
상기 제조예 2를 통해 제조된 유효성분 100 중량부에 상기 제조예 3을 통해 제조된 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀 5 중량부를 혼합하고 150rpm의 속도로 10분 동안 교반하여 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물을 제조하였다.5 parts by weight of the polymersome containing the polyelastic acid (PLLA) prepared in Preparation Example 3 was mixed with 100 parts by weight of the active ingredient prepared in Preparation Example 2, and stirred at a speed of 150 rpm for 10 minutes to polyelac. A cosmetic composition for improving skin wrinkles using tic acid (PLLA) was prepared.
<실시예 2><Example 2>
상기 실시예 1과 동일하게 진행하되, 상기 제조예 3을 통해 제조된 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀 0.1 중량부를 혼합하여 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물을 제조하였다.Proceed in the same manner as in Example 1, but by mixing 0.1 part by weight of the polyellactic acid (PLLA)-containing polymersome prepared in Preparation Example 3 to improve skin wrinkles using polyelastic acid (PLLA). was manufactured.
<실시예 3><Example 3>
상기 실시예 1과 동일하게 진행하되, 상기 제조예 3을 통해 제조된 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀 10 중량부를 혼합하여 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물을 제조하였다.Proceed in the same manner as in Example 1, but mix 10 parts by weight of the polymersome containing polyelastic acid (PLLA) prepared in Preparation Example 3, and use a cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA). was manufactured.
<실시예 4><Example 4>
상기 실시예 1과 동일하게 진행하되, 상기 제조예 2를 통해 제조된 유효성분에 함유된 글리세린 100 중량부 대비 상기 제조예 4를 통해 제조된 들깻잎 추출물 3 중량부를 더 혼합하여 피부노화 방지용 화장료 조성물을 제조하였다.Proceed in the same manner as in Example 1, but further mix 3 parts by weight of the perilla leaf extract prepared in Preparation Example 4 with respect to 100 parts by weight of glycerin contained in the active ingredient prepared in Preparation Example 2 to obtain a cosmetic composition for preventing skin aging manufactured.
<비교예 1><Comparative Example 1>
글리세린 80.2g, 정제수 12mL, 카프릴릭/카프릭트라이글리세라이드 5g, 하이드로제네이티드레시틴 2g, 콜레스테롤 0.5g, 소듐하이알루로네이트 0.1g, 콜라겐 0.1g 및 하이드롤라이즈드엘라스틴 0.1g을 혼합하여 피부노화 방지용 화장료 조성물을 제조하였다.Glycerin 80.2g, purified water 12mL, caprylic/capric triglyceride 5g, hydrogenated lecithin 2g, cholesterol 0.5g, sodium hyaluronate 0.1g, collagen 0.1g and hydrolyzed elastin 0.1g were mixed A cosmetic composition for preventing skin aging was prepared.
상기 실시예 1을 통해 제조된 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물의 물성을 측정하여 아래 표 1에 나타내었다.The physical properties of the cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA) prepared in Example 1 were measured and are shown in Table 1 below.
<표 1><Table 1>
또한, 본 발명의 실시예 1을 통해 제조된 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물의 피부독성을 측정하여 아래 표 3에 나타내었다.In addition, the skin toxicity of the cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA) prepared in Example 1 of the present invention was measured and shown in Table 3 below.
[단, 피부독성은 ISO 10993-5방법을 이용하였으며, 생존율 70% 이상은 세포독성이 없다고 판별한다.[However, for skin toxicity, the ISO 10993-5 method was used, and a survival rate of 70% or more was determined to have no cytotoxicity.
* 세포주: Vero Cell ( African Green Monkey, KCLB No - 10081)* Cell line: Vero Cell (African Green Monkey, KCLB No - 10081)
* 사용시약: Dubelcco’s Modified Eagle’s Medium (DMEM, Sigma), Kanamycin sulfate (SAMCHUN), Sodium bicarbonate (DUKSAN), Antibiotic-Antimyotic (GenDEPOT), Fetal bovine serum (GenDEPOT)* Reagents: Dubelcco’s Modified Eagle’s Medium (DMEM, Sigma), Kanamycin sulfate (SAMCHUN), Sodium bicarbonate (DUKSAN), Antibiotic-Antimytic (GenDEPOT), Fetal bovine serum (GenDEPOT)
* 용매: DMEM 배지 + 10% FBS * Solvent: DMEM medium + 10% FBS
* 시험조건: 세포와 시료용출액을 24시간 동안 접촉한 후 Thiazolyl Blue Tetrazolium Bromide 시약을 처리하여 570 nm에서 흡광도를 측정 * Test conditions: After contacting the cells and the sample eluate for 24 hours, the absorbance is measured at 570 nm by treating with Thiazolyl Blue Tetrazolium Bromide reagent.
* 대조군: 음성대조군-Phosphate Buffer Saline, 양성대조군-Dimethyl sulfoxide, 용매대조군-용매 * Control group: negative control group-Phosphate Buffer Saline, positive control group-Dimethyl sulfoxide, solvent control group-solvent
* 결과 표기 방법: 생존율(%)은 하기의 식을 이용해 계산하였다. * Result notation method: Survival rate (%) was calculated using the following formula.
생존율(%) = {(시료처리군 OD570 / 시료 미처리군 OD570) / (시료 미 처리군 OD570 - 시료 미처리군 OD650)} × 100] Survival rate (%) = {(Sample treated group OD570 / Sample untreated group OD570) / (Sample untreated group OD570 - Sample untreated group OD650)} × 100]
<표 2><Table 2>
<표 3><Table 3>
상기 표 1에 나타낸 것처럼, 본 발명의 실시예 1을 통해 제조된 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물을 피부독성이 낮은 것을 알 수 있다.As shown in Table 1, it can be seen that the cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA) prepared in Example 1 of the present invention has low skin toxicity.
또한, 상기 실시예 1 내지 4 및 비교예 1을 통해 제조된 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물의 주름개선 효과를 측정하여 아래 표 4에 나타내었다.In addition, the anti-wrinkle effect of the cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA) prepared in Examples 1 to 4 and Comparative Example 1 was measured and shown in Table 4 below.
{단, 주름개선 효과는 눈가에 주름이 발생된 30~50대 여성 50명을 대상으로 제조된 화장료 조성물을 주름이 발생된 눈가에 하루 2g씩 4주 동안 도포하도록 한 후에 개선정도를 3점 척도법으로 측정하여 평균값으로 나타내는 방법을 이용하였다.{However, for the wrinkle improvement effect, apply the cosmetic composition prepared for 50 women in their 30s to 50s with wrinkles around the eyes for 4 weeks, 2g per day for 4 weeks, and then measure the degree of improvement using a 3-point scale method was measured and expressed as an average value.
3점:매우 개선, 2점:약간 개선, 3점:개선 없음}3 points: very improved, 2 points: slightly improved, 3 points: no improvement}
<표 4><Table 4>
상기 표 4에 나타낸 것처럼, 본 발명의 실시예 1 내지 4를 통해 제조된 화장료 조성물은 비교예 1에 비해 우수한 주름개선 효과를 나타내는 것을 알 수 있다.As shown in Table 4, it can be seen that the cosmetic composition prepared through Examples 1 to 4 of the present invention exhibits an excellent anti-wrinkle effect compared to Comparative Example 1.
따라서, 본 발명에 따른 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물은 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부노화 방지 효과를 나타낼 뿐만 아니라, 피부독성이 낮아 피부트러블을 유발하지 않는 효과를 나타낸다.Therefore, the cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA) according to the present invention can be applied to the MTS method and exhibits excellent skin aging prevention effects due to improved skin penetration effect, as well as low skin toxicity. It shows an effect that does not cause trouble.
Claims (8)
상기 유효성분은 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 함유되고,
상기 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 120 내지 200 나노미터로 에멀전화되는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물.
It consists of 0.1 to 10 parts by weight of polymersomes containing 100 parts by weight of active ingredients and polyelastic acid (PLLA),
The active ingredient contains sodium hyaluronate, collagen and hydrolyzed elastin,
A cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA), characterized in that the sodium hyaluronate, collagen and hydrolyzed elastin are emulsified to 120 to 200 nanometers.
상기 유효성분은 글리세린, 정제수, 카프릴릭/카프릭트라이글리세라이드, 하이드로제네이티드레시틴, 콜레스테롤, 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴으로 이루어지는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물.
The method of claim 1,
The active ingredient is polyelastic acid (PLLA), characterized in that it consists of glycerin, purified water, caprylic / capric triglyceride, hydrogenated lecithin, cholesterol, sodium hyaluronate, collagen and hydrolyzed elastin ) Cosmetic composition for improving skin wrinkles using.
상기 유효성분은 글리세린 100 중량부, 정제수 13 내지 17 중량부, 카프릴릭/카프릭트라이글리세라이드 5 내지 7 중량부, 하이드로제네이티드레시틴 2 내지 3 중량부, 콜레스테롤 0.5 내지 0.7 중량부, 소듐하이알루로네이트 0.1 내지 0.15 중량부, 콜라겐 0.1 내지 0.15 중량부 및 하이드롤라이즈드엘라스틴 0.1 내지 0.15 중량부으로 이루어지는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물.
The method of claim 2,
The active ingredient is glycerin 100 parts by weight, purified water 13 to 17 parts by weight, caprylic / capric triglyceride 5 to 7 parts by weight, hydrogenated lecithin 2 to 3 parts by weight, cholesterol 0.5 to 0.7 parts by weight, sodium high A cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA), comprising 0.1 to 0.15 parts by weight of alluronate, 0.1 to 0.15 parts by weight of collagen, and 0.1 to 0.15 parts by weight of hydrolyzed elastin.
상기 폴리엘락틱엑시드(PLLA)가 함유된 폴리머좀은 폴리엘락틱엑시드(PLLA)와 폴리에틸렌글리콜이 5:2로 혼합된 혼합물에 팔미토일트리펩타이드를 첨가하여 제조되는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물.
The method of claim 1,
The polyelastic acid (PLLA)-containing polymersome is prepared by adding palmitoyl tripeptide to a mixture of polyelastic acid (PLLA) and polyethylene glycol in a ratio of 5: 2. A cosmetic composition for improving skin wrinkles using (PLLA).
상기 유효성분에는 상기 유효성분에 함유된 글리세린 100 중량부 대비 들깻잎 추출물 0.1 내지 5 중량부가 더 함유되는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물.
The method of claim 1,
A cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA), characterized in that the active ingredient further contains 0.1 to 5 parts by weight of perilla leaf extract compared to 100 parts by weight of glycerin contained in the active ingredient.
상기 들깻잎 추출물은 들깻잎 100 중량부에 탄소수가 1 내지 4인 저급알코올 200 내지 1000 중량부를 혼합하고 추출하여 제조되는 것을 특징으로 하는 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물.
The method of claim 6,
The perilla leaf extract is prepared by mixing and extracting 200 to 1000 parts by weight of lower alcohol having 1 to 4 carbon atoms in 100 parts by weight of perilla leaves. A cosmetic composition for improving skin wrinkles using polyelastic acid (PLLA).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220165076A KR102553815B1 (en) | 2022-11-30 | 2022-11-30 | Cosmetic composition for preventing skin aging using poly-l-lactic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220165076A KR102553815B1 (en) | 2022-11-30 | 2022-11-30 | Cosmetic composition for preventing skin aging using poly-l-lactic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102553815B1 true KR102553815B1 (en) | 2023-07-10 |
Family
ID=87155911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220165076A KR102553815B1 (en) | 2022-11-30 | 2022-11-30 | Cosmetic composition for preventing skin aging using poly-l-lactic acid |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102553815B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100564108B1 (en) | 2004-01-12 | 2006-03-24 | 주식회사 생그린 | Cosmetic composition comprising plant extract having anti-aging effect |
KR20110013147A (en) * | 2009-07-31 | 2011-02-09 | (주)아모레퍼시픽 | Cosmetic composition containing polymersomes encapsulated peptides or hydrolyzed millet |
KR20110036664A (en) * | 2009-10-02 | 2011-04-08 | 가부시키가이샤 페이스 | Cosmetic base comprising collagen-modified liposome and skin cosmetic containing the same |
KR20170037570A (en) * | 2015-09-25 | 2017-04-04 | 서울대학교산학협력단 | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf |
KR102224032B1 (en) | 2020-08-27 | 2021-03-08 | 주식회사 에이치앤비나인 | Active ingredient for skin anti-aging and cosmetic composition comprising the same |
KR102342695B1 (en) * | 2021-07-14 | 2021-12-24 | 에이드코리아컴퍼니 주식회사 | Cosmetic composition for skin soothing |
-
2022
- 2022-11-30 KR KR1020220165076A patent/KR102553815B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100564108B1 (en) | 2004-01-12 | 2006-03-24 | 주식회사 생그린 | Cosmetic composition comprising plant extract having anti-aging effect |
KR20110013147A (en) * | 2009-07-31 | 2011-02-09 | (주)아모레퍼시픽 | Cosmetic composition containing polymersomes encapsulated peptides or hydrolyzed millet |
KR20110036664A (en) * | 2009-10-02 | 2011-04-08 | 가부시키가이샤 페이스 | Cosmetic base comprising collagen-modified liposome and skin cosmetic containing the same |
KR20170037570A (en) * | 2015-09-25 | 2017-04-04 | 서울대학교산학협력단 | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf |
KR102224032B1 (en) | 2020-08-27 | 2021-03-08 | 주식회사 에이치앤비나인 | Active ingredient for skin anti-aging and cosmetic composition comprising the same |
KR102342695B1 (en) * | 2021-07-14 | 2021-12-24 | 에이드코리아컴퍼니 주식회사 | Cosmetic composition for skin soothing |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102256061B1 (en) | Method for crosslinking hyaluronic acid, method for preparing an injectable hydrogel, hydrogel obtained and use of the obtained hydrogel | |
US20220401337A1 (en) | Stem cell stimulating compositions and methods | |
JPWO2002098372A1 (en) | Acidic external use composition and cosmetics containing the same, hair restorer, penetration enhancer for external use such as skin | |
CA2647775C (en) | Synthetic peptides useful in the treatment of the skin and use thereof in cosmetic or dermopharmaceutical compositions | |
WO2014044808A2 (en) | Fast-penetration cosmetic dermal filler for topical application | |
KR102452905B1 (en) | the method for skin improvement cosmetic composition containing natural spicule and polydioxanone and the cosmetic composition thereof | |
US20210244794A1 (en) | Stem Cell Stimulating Compositions for Treatment of Melasma | |
US20040162232A1 (en) | Elastin digest compositions and methods utilizing same | |
KR101895038B1 (en) | Dissolvable film comprising spicule and use thereof | |
JP3504205B2 (en) | External preparation for skin | |
CN112294666A (en) | Silica gel eye cream with permeation promoting function | |
KR20190010795A (en) | Moisturizing, anti-wrinkling, and whitening cosmetic composition comprising novel Hyalpol Matrix Mixture and preparation method of the same | |
EP4257116A1 (en) | Method for producing spicule coated with active ingredient for skin improvement and diamond, and diamond spicule cosmetic composition comprising same | |
KR101895037B1 (en) | Hydrogel comprising spicule and use thereof | |
JP2000273033A (en) | Gel comprising natural material | |
JP6883723B2 (en) | Liposomes, liposome solutions and cosmetics, and methods for producing the above liposomes. | |
KR102553815B1 (en) | Cosmetic composition for preventing skin aging using poly-l-lactic acid | |
KR101917026B1 (en) | Cosmetic composition for skin wrinkle improvement and prevention | |
JP3342050B2 (en) | Cosmetics | |
KR20230111926A (en) | A cosmetic composition comprising vegetable collagens using natural microneedle, and a manufacturing process thereof | |
KR20070119971A (en) | Functional cosmetic including nano silver | |
JPH0778026B2 (en) | Topical base for skin | |
KR100924643B1 (en) | Methods of Producing and liposomes entrapping atelocollagen | |
JPH07196520A (en) | Modified chitosan composition | |
KR20230150413A (en) | Spicule coated with diamond and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |